Evidence map›Paper›PMID 34858989›Full record

ReviewFrontiers in cell and developmental biology2021

Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology.

Rebekka Kühn, Aayushi Mahajan, Peter Canoll, Gunnar Hargus

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rebekka KühnDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States.
Aayushi MahajanDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States.
Peter CanollDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States.
Gunnar HargusDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States.
Columbia University · US

Funding

Elucidating the Role of Microglia and Neurotrophin Receptor p75 on Neuronal Degeneration in Frontotemporal DementiaK08NS116166 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HARGUS, GUNNAR · 2021 to 2025
$968k
Using a human stem cell model of tauopathy to evaluate the effects of tau filaments on cell metabolism at a single cell level in vitro and in vivoR21AG070414 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HARGUS, GUNNAR · 2020 to 2020
$446k
Application of single cell sequencing to study astrocyte-mediated neuronal degeneration in a stem cell model of frontotemporal dementiaR03NS112785 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HARGUS, GUNNAR · 2019 to 2020
$162k
NIA NIH HHS R21 AG070414NINDS NIH HHS K08 NS116166NINDS NIH HHS R03 NS112785
6 · The paper itself

Abstract

Neurodegenerative dementias are the most common group of neurodegenerative diseases affecting more than 40 million people worldwide. One of these diseases is frontotemporal dementia (FTD), an early onset dementia and one of the leading causes of dementia in people under the age of 60. FTD is a heterogeneous group of neurodegenerative disorders with pathological accumulation of particular proteins in neurons and glial cells including the microtubule-associated protein tau, which is deposited in its hyperphosphorylated form in about half of all patients with FTD. As for other patients with dementia, there is currently no cure for patients with FTD and thus several lines of research focus on the characterization of underlying pathogenic mechanisms with the goal to identify therapeutic targets. In this review, we provide an overview of reported disease phenotypes in induced pluripotent stem cell (iPSC)-derived neurons and glial cells from patients with tau-associated FTD with the aim to highlight recent progress in this fast-moving field of iPSC disease modeling. We put a particular focus on genetic forms of the disease that are linked to mutations in the gene encoding tau and summarize mutation-associated changes in FTD patient cells related to tau splicing and tau phosphorylation, microtubule function and cell metabolism as well as calcium homeostasis and cellular stress. In addition, we discuss challenges and limitations but also opportunities using differentiated patient-derived iPSCs for disease modeling and biomedical research on neurodegenerative diseases including FTD.

Indexed as

disease modelingfrontotemporal dementia (FTD)frontotemporal lobar degeneration (FTLD)induced pluriopotent stem cellsneurodegenenerative diseasesneurodegenerationtautauopathy

Identifiers

PMID34858989
PMCPMC8631302
OpenAlexW3213685179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.